Zhu 2024 - Ecnoglutide Phase 2 Trial in Type 2 Diabetes

Nature Communications·September 27, 2024

Dalong Zhu, Weimin Wang, Guoyu Tong, Guoqing Ma, Jianhua Ma, Jie Han, Xin Zhang, Yang Liu, Shenglian Gan, Hong Qin, Qing Zheng, Jing Ning, Zhiyi Zhu, Mengying Guo, Yue Bu, Yao Li, Catherine L. Jones, Martijn Fenaux, Mohammed K. Junaidi, Susan Xu, Hai Pan

Summary

Ecnoglutide significantly reduced HbA1c and body weight versus placebo in adults with type 2 diabetes and was generally well tolerated.

Study Details

Study Design

Phase 2 randomized, double-blind, placebo-controlled trial

Indication

Type 2 diabetes

Intervention

Once-weekly ecnoglutide 0.4, 0.8, or 1.2 mg vs placebo for 20 weeks

Species

Human

Sample Size

145 subjects

Risk of Bias Assessment

Sponsor-funded by Sciwind Biosciences